Brief: INmune Bio’s INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints
04/08/2025 13:22
Aug 4 (Reuters) - INmune Bio Inc INMB.O: INMUNE BIO’S CARE PC TRIAL OF INKMUNE™ IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER MEETS ENDPOINTS AND IS CLOSED TO ENROLLMENT INMUNE BIO INC - INKMUNE WELL TOLERATED WITH EXCELLENT SAFETY PROFILE INMUNE BIO INC - PLANS PHASE 2B TRIAL FOR LESS SEVERE DISEASE Source text: ID:nGNX6K2j2r Further company coverage: INMB.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Inmune Bio
See all newsBrief: Inmune Bio - Enters Master Services Agreement With Uniphar For Ebstrocel International Commercialization
Brief: Inmune Bio Targets UK Maa In Q4 2026, EU Maa And US BLA In Q1 2027
INmune Bio Inc reports results for the quarter ended June 30 - Earnings Summary
INmune Bio Q2 net loss narrows on lower impairment charges
INmune Bio Inc expected to post a loss of 21 cents a share - Earnings Preview